Viking Therapeutics, Inc. VKTX

Key data

The business

Viking Therapeutics sells nothing. It is a clinical-stage company with one drug that matters, VK2735, aimed at the largest new market in medicine. VK2735 comes two ways, a weekly injection and a daily pill, and both work the same way as Lilly's Zepbound and Novo's Wegovy, switching on two gut-hormone receptors, GLP-1 and GIP, that tell the body it is full (10-Q, filed 2026-07-29). The injection is the lead, moving through late-stage trials. The pill sits a step behind and is the bigger prize, because an oral obesity drug that actually works is something only Lilly has demonstrated to date based on publicly available data. The mechanism itself is proven and stated in the filing, which is both comfort and threat: comfort because it is de-risked, threat because the field is now crowded with giants. The pivotal weight-loss numbers that will settle the stock are not in this run's evidence, and with no literature search available I found no primary published source to cite for them. Everything Viking is worth rides on those two molecules clearing their trials and then being launched or bought. There is no second act on the shelf.

The numbers

The only line that moves here is the loss, and it is moving the wrong way fast.

The quarterly loss roughly doubled from $65.6 million a year ago to a $158.3 million peak last winter as late-stage programs ramped, then eased to $128.0 million. Do not read the rising cash column as health: the jump through late 2025 was a financing, not the business, and cash equivalents are only part of Viking's money, with the rest held in investments. The tell is that losses ran wider than the Street's estimate in three of the last four quarters, missing by as much as $0.49 a share. The balance sheet is melting faster than the models said.

There is no P/E because there has never been a profit, in twelve years or ever. So price it the honest way, on book: at 9.9 times, the stock is dearer than at any year-end in its history, the prior high being about 7.8x back in 2017. The compounding math that matters is not earnings, it is burn against milestones. Operating cash burn hit $114.0 million in a single quarter and is accelerating. Consensus does not see a dollar of meaningful revenue until 2028, then about $474 million in 2029, with losses the whole way. What the market believes and I do not is that Viking gets to the finish line without a large, dilutive raise on the market's terms rather than its own. The print that settles it is the next cash line read against any shelf or ATM usage.

Management

The record here is written in insider sales. Over twelve months, one buy worth $150 thousand against twenty sales worth $22.3 million. CEO Brian Lian sold $4.9 million of stock on July 29, 2026, the same day the company printed its Q2 loss, after selling $4.3 million in January. Plan status is not disclosed in this run's data, so I cannot separate scheduled 10b5-1 sales from discretionary ones, and that matters, because a lump with no footnote hides which it is. There is no product profit for pay to reward and no real buyback, both normal for a clinical biotech. What I can say is that the people who know the trial data best have been consistent net sellers into every rally.

How it fails or surprises you

The pivotal readout. The whole $4 billion rests on the late-stage injection data showing weight loss in the neighborhood of twenty percent of body weight with tolerable side effects. Miss on efficacy or, more likely, on how many patients quit over nausea, and the stock re-rates hard toward its cash. The window is 2027 into 2028, and no amount of balance sheet fixes a bad curve.

Financing before the answer. Working capital of $407.9 million against a $114.0 million quarterly burn is under four quarters of room on the conservative measure, and burn is rising. A raise before the pivotal data is close to certain, dilutive at whatever price the market sets, and the wider-than-modeled losses mean it may come sooner and bigger than bulls assume.

A takeout (right tail). Viking is one of the few independent, late-stage obesity assets left, and every large pharma without a winning GLP-1 wants one. An acquisition, or an ex-US license carrying a large upfront that erases the dilution overhang, is not priced today because the company has signaled it will go alone. The print would be a deal 8-K, and it could arrive at a multiple of today's price.

Closing thoughts

This is a stock where one number decides almost everything and you must survive to see it. The late-stage injection readout converts $4 billion into either a genuine obesity franchise worth many times that or a busted single-asset story worth its cash, and the survival question, financing through the wait, sits on top. The right tail is genuinely fat here: the market is enormous, the mechanism is proven, and the asset is scarce enough to be bought. But the left tail is real and permanent, a tolerability miss paired with a forced raise, and there is no diversified pipeline to cushion it. On the evidence, the odds look roughly balanced between a large up move and a severe down move, which is my judgment, not a measured probability. What is at risk if the downside linchpin breaks is most of the equity. What the upside is worth if the drug lands is a company several times this size.

The bet is still what it was: that VK2735, the shot and the pill, takes about twenty percent of people's weight off cleanly and claims a slice of the obesity market. It breaks if the pivotal curve disappoints or the money runs short first, and the one pair of numbers that tells you earliest is working capital of $407.9 million against a burn of $114.0 million a quarter. If Viking reaches its readout without a punishing raise, the bet is alive. If the next cash line drops and a discounted offering follows, the market answered before the trial did.